-2.07%
35.84%
39.78%
77.01%
224.41%
264.68%
440.25%
AI Spotlight on CORT
Company Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States.The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess.
The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays.Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Market Data
| Last Price | 68.45 |
| Change Percentage | -2.07% |
| Open | 70.05 |
| Previous Close | 69.9 |
| Market Cap ( Millions) | 7172 |
| Volume | 480311 |
| Year High | 71.29 |
| Year Low | 20.84 |
| M A 50 | 55.58 |
| M A 200 | 40.63 |
Financial Ratios
| FCF Yield | 1.99% |
| Dividend Yield | 0.00% |
| ROE | 24.68% |
| Debt / Equity | 1.06% |
| Net Debt / EBIDTA | -90.59% |
| Price To Book | 11.08 |
| Price Earnings Ratio | 50.08 |
| Price To FCF | 50.29 |
| Price To sales | 11.41 |
| EV / EBITDA | 48.88 |
News
- Jan -29 - Big Money Keeps Buying Corcept
- Jan -29 - Buy These 5 Stocks With Recent Price Strength Amid a Volatile January
- Jan -24 - Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"
- Jan -24 - Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm
- Jan -22 - Corcept Therapeutics Generating Strong Revenue And Profit Growth
- Jan -22 - Medical Stock Soars To Highs As Cortisol Screening Grows
- Dec -31 - Corcept Submits Application for Another Cushing's Syndrome Drug
- Dec -12 - CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
- Dec -11 - Corcept Therapeutics' ALS drug fails in mid-stage trial
- Dec -06 - Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?
- Nov -27 - Corcept Therapeutics: A Most Promising And Compelling Biotech
- Nov -22 - Corcept Shares Rise More Than 60% in Three Months: Here's Why
- Nov -21 - 3 Reasons Growth Investors Will Love Corcept (CORT)
- Nov -20 - Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet
- Nov -20 - Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable
- Nov -11 - Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
- Nov -08 - 5 Stocks With Recent Price Strength to Tap Wall Street Rally
- Nov -08 - 5 Small Drug Stocks to Buy as Trump Gets Re-Elected
- Nov -06 - Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?
- Nov -05 - Here is Why Growth Investors Should Buy Corcept (CORT) Now
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceutical
Expected Growth : 14 %
What the company do ?
Corcept Therapeutics Incorporated is a pharmaceutical company that develops and commercializes medications for the treatment of severe metabolic and endocrine disorders.
Why we expect these perspectives ?
Corcept Therapeutics' 14% growth is driven by increasing adoption of Korlym, its Cushing's syndrome treatment, and growing sales of its oncology portfolio. Strong demand for Korlym, coupled with expanded label indications and increased physician awareness, contribute to the company's growth momentum.
Corcept Therapeutics Incorporated Products
| Product Range | What is it ? |
|---|---|
| Korlym | A glucocorticoid receptor antagonist indicated to control hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance. |
| Korlym (mifepristone) 300 mg tablets | A once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome. |
Corcept Therapeutics Incorporated's Porter Forces
Threat Of Substitutes
Corcept Therapeutics Incorporated has a moderate threat of substitutes due to the availability of alternative treatments for Cushing's syndrome and other endocrine disorders.
Bargaining Power Of Customers
Corcept Therapeutics Incorporated has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative treatment options.
Bargaining Power Of Suppliers
Corcept Therapeutics Incorporated has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and manufacturing services.
Threat Of New Entrants
Corcept Therapeutics Incorporated has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including regulatory hurdles and significant research and development investments.
Intensity Of Rivalry
Corcept Therapeutics Incorporated operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.03% |
| Debt Cost | 3.95% |
| Equity Weight | 99.97% |
| Equity Cost | 6.44% |
| WACC | 6.44% |
| Leverage | 0.03% |
Corcept Therapeutics Incorporated : Quality Control
Corcept Therapeutics Incorporated passed 7 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| NVAX | Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a … |
| ACLX | Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which … |
| RPRX | Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, … |
| ALPN | Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline … |
| EXEL | Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Exelixis
A-Score
1-Year Total Return ->
🥈
Royalty Pharma
A-Score
1-Year Total Return ->
🥉
Corcept Therapeutics
A-Score
1-Year Total Return ->
4
Novavax
A-Score
1-Year Total Return ->
5
Alpine Immune Sciences
A-Score
1-Year Total Return ->
6
